Allurion Technologies Inc. (ALUR)
NYSE: ALUR · Real-Time Price · USD
2.680
-0.080 (-2.90%)
At close: Aug 8, 2025, 4:00 PM
2.610
-0.070 (-2.61%)
After-hours: Aug 8, 2025, 7:36 PM EDT
Revance Therapeutics Stock Forecast
ALUR's stock price has decreased by -85.62% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts that cover Revance Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $22.83, which forecasts a 751.87% increase in the stock price over the next year. The lowest target is $2.50 and the highest is $50.
Price Target: $22.83 (+751.87%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 27, 2025.
Analyst Ratings
The average analyst rating for Revance Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Hold Maintains $2.5 | Hold | Maintains | $2.5 | -6.72% | Mar 27, 2025 |
| Roth MKM | Roth MKM | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +497.01% | Mar 21, 2025 |
| Chardan Capital | Chardan Capital | Hold Maintains $2.5 | Hold | Maintains | $2.5 | -6.72% | Mar 21, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 14, 2024 |
| TD Cowen | TD Cowen | Strong Buy Initiates $50 | Strong Buy | Initiates | $50 | +1,765.67% | Oct 2, 2024 |
Financial Forecast
Revenue This Year
29.55M
from 32.11M
Decreased by -7.98%
Revenue Next Year
44.14M
from 29.55M
Increased by 49.37%
EPS This Year
-0.22
from -11.64
EPS Next Year
-1.97
from -0.22
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 31.5M | 55.1M | 65.6M |
| Avg | 29.5M | 44.1M | 52.1M |
| Low | 25.6M | 31.7M | 38.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.9% | 86.6% | 48.7% |
| Avg | -8.0% | 49.4% | 18.0% |
| Low | -20.4% | 7.4% | -12.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.14 | 2.16 | -1.62 |
| Avg | -0.22 | -1.97 | -3.65 |
| Low | -0.29 | -7.87 | -5.50 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.